Prospective Lifespan Cohort of Myocardial Infarction

March 22, 2026 updated by: Kaiyang Lin, Fujian Provincial Hospital

A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System

This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.

The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.

The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

6000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Fuzhou University Affiliated Provincial Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adults aged 18 to 74 years will be enrolled into two cohorts: a high-risk population cohort including individuals with stable angina or unstable angina, and a confirmed acute myocardial infarction cohort including patients diagnosed according to the Fourth Universal Definition of Myocardial Infarction. All participants must be able to provide informed consent and complete baseline assessment, biospecimen collection, and longitudinal follow-up.

Description

Inclusion Criteria:

Age 18 to 74 years

Diagnosed with stable angina, unstable angina, or acute myocardial infarction

For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized

Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction

Willing to participate and able to provide written informed consent

Able to complete baseline assessment, biospecimen collection, and long-term follow-up

Exclusion Criteria:

End-stage malignant tumor with expected survival of less than 1 year

Severe hepatic or renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m² or Child-Pugh class C)

Active autoimmune disease or long-term use of immunosuppressive agents

Pregnant or breastfeeding women

Inability to provide informed consent or severe cognitive impairment

Previous participation in another clinical study that may conflict with this project

Any other condition considered by the investigators to make participation inappropriate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
High-risk Population
Participants at high risk of acute myocardial infarction, including individuals with stable angina or unstable angina, with or without silent myocardial ischemia, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.
Confirmed Acute Myocardial Infarction Population
Participants with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction, including type 1, 2, 3, 4a, 4b, 4c, and 5 myocardial infarction, as well as myocardial infarction with non-obstructive coronary arteries when applicable, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of all-cause mortality
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Rate of cardiovascular death
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years
Rate of recurrent myocardial infarction
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years
Rate of readmission due to heart failure
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years
Rate of target vessel or non-target vessel revascularization
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years
Rate of stroke
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years
Rate of definite or probable stent thrombosis
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years
Rate of severe bleeding
Time Frame: From enrollment to the end of study follow-up, up to 5 years
From enrollment to the end of study follow-up, up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fujian Provincial Hospital

Investigators

  • Principal Investigator: Kaiyang Lin, PhD, Fuzhou University Affiliated Provincial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 10, 2026

Primary Completion (Estimated)

April 10, 2031

Study Completion (Estimated)

April 10, 2031

Study Registration Dates

First Submitted

March 10, 2026

First Submitted That Met QC Criteria

March 10, 2026

First Posted (Actual)

March 13, 2026

Study Record Updates

Last Update Posted (Actual)

March 25, 2026

Last Update Submitted That Met QC Criteria

March 22, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • K2026-03-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stable Angina

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe